• Aerie Pharmaceuticals
    Comprehensive Ophthalmology

    Aerie Pharmaceuticals reported a net loss of $10.3 million for the fourth quarter of 2013, compared to $3.8 million for the fourth quarter of 2012, as well as  a net loss of $31.6 million for all of 2013, compared to $15.6 million in 2012.

    Aerie did not comment directly on these results but did note that the $10.3 million net loss for the fourth quarter included $6.8 million in operating  expenses and non-cash charges totaling $4.9 million. 

    As of Feb. 28, 2014, Aerie had $67.6 million in cash and marketable securities on its balance sheet, representing almost the full net proceeds from its initial public offering in October 2013. This amount is expected to fund phase 3 development of Rhopressa, a Rho Kinase inhibitor targeting the trabecular meshwork, and phase 2 development of Roclatan, a prostaglandin analogue.